Friday, April 04, 2025 6:01:47 PM
Let's go over this. NWBO probably canceled ASCO mid Dec early Jan when they were all hands on deck with MID inspections and back and forth with the MHRA. Canceled it because ASCO demanded all the bolded deadlines as I posted to you. See here https://conferences.asco.org/am/dates-know
Now mid-Dec /early Jan NWBO management has to make a choice or invest scarce resources (Bosch Liau) to meet the deadlines ASCO demanded in Dec, Jan, Feb, March, and April OR stay fully focussed on MHRA on-site inspections and what comes after that. They decided, back then, tostay focus on the MHRA. And yes the bold part of what I posted about what needs to be done to prepare for Asco takes up a lot of time for people such as Liau and or Bosch.
Next the 10K was the first opportunity for them to let everyone know they canceled ASCO in mid-December/Early Jan.
Your theory really does not hold Mike. Also why would you think they are lying in an official sec document?
Now mid-Dec /early Jan NWBO management has to make a choice or invest scarce resources (Bosch Liau) to meet the deadlines ASCO demanded in Dec, Jan, Feb, March, and April OR stay fully focussed on MHRA on-site inspections and what comes after that. They decided, back then, tostay focus on the MHRA. And yes the bold part of what I posted about what needs to be done to prepare for Asco takes up a lot of time for people such as Liau and or Bosch.
Next the 10K was the first opportunity for them to let everyone know they canceled ASCO in mid-December/Early Jan.
Your theory really does not hold Mike. Also why would you think they are lying in an official sec document?
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
